Clinical Trials Logo

Filter by:
NCT ID: NCT03752970 Completed - Crohn Disease Clinical Trials

A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

Start date: February 5, 2019
Phase: Phase 2
Study type: Interventional

This is a study in adults with Crohn's Disease who also have fistulas near the anus. The study has 2 parts. The first part is to find out more about what causes the fistulas. In this part of the study, tissue samples are taken from patients. The second part of the study tests whether a medicine called spesolimab (BI 655130) helps patients with Crohn's Disease. Participants get study medication for 24 weeks. The participants are put into 2 groups. It is decided by chance who gets into which group. One group gets an intravenous drip that contains spesolimab every 4 weeks. The other group gets a placebo drip every 4 weeks. The placebo drip looks like the spesolimab drip, but contains no medicine. The doctors regularly examine fistulas of the participants. The results of the fistula examinations are compared between the groups. The doctors also check the general health of the patients.

NCT ID: NCT03752437 Completed - Clinical trials for Extracorporeal Circulation; Complications

Comparison of Two Dosages of Heparin Before Extracorporeal Circulation

Start date: October 1, 2019
Phase: Phase 4
Study type: Interventional

In this study the investigators will study two dosages of heparin before extracorporeal circulation in open chest cardiac surgery.

NCT ID: NCT03752151 Completed - Clinical trials for Atrioventricular Conduction Block

Micra Atrial TRacking Using A Ventricular AccELerometer 2

MARVEL2
Start date: January 22, 2019
Phase: N/A
Study type: Interventional

The purpose of the Micra Atrial TRacking Using A Ventricular AccELerometer 2 (MARVEL 2) study is to demonstrate safe and effective operation of the MARVEL 2 features for providing AV synchronous pacing in patients with normal sinus node function and AV block

NCT ID: NCT03751007 Completed - Diabetes type1 Clinical Trials

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

Start date: October 24, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab in participants with recent-onset type 1 diabetes (T1D).

NCT ID: NCT03749668 Completed - Colorectal Surgery Clinical Trials

Dietary Survey After Colorectal Surgery Within an Enhanced Recovery Program (DIETERP).

DIETERP
Start date: November 15, 2018
Phase:
Study type: Observational

This observational study will quantify caloric-protein intake in 75 patients undergoing colorectal surgery within an enhanced recovery program at CHU Liège. A dietary survey will be performed preoperatively and repeated postoperatively via telephone calls on Day + 3, Day + 7; Day + 15, and Day + 30, after leaving the hospital. The deficits observed will be correlated with the medical and surgical characteristics of the patients

NCT ID: NCT03748823 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Start date: February 19, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate pharmacokinetics (PK) of ravulizumab administered subcutaneously via an on-body delivery system (OBDS) compared with intravenously administered ravulizumab in adult participants with PNH who are clinically stable on eculizumab for at least 3 months prior to study entry.

NCT ID: NCT03748134 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Start date: December 24, 2018
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in subjects representing the western population with advanced esophageal squamous cell carcinoma

NCT ID: NCT03747939 Completed - Clinical trials for Arthritis, Psoriatic

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

FOREMOST
Start date: December 31, 2018
Phase: Phase 4
Study type: Interventional

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 285 patients worldwide will take part in this study.

NCT ID: NCT03747679 Completed - CML Clinical Trials

Palatability (Taste) of Oral Formulations of Bosutinib

Start date: November 22, 2018
Phase: Phase 1
Study type: Interventional

Healthy Adult Volunteer Taste Study of Oral Formulations of Bosutinib for Pediatric Use. This will be a single-blind, randomized, multiple-period (dosing over 4 days) study in healthy male and/or female participants. Approximately 8 participants will assess the sensory attributes of different powder for oral suspension (POS) formulations.

NCT ID: NCT03746691 Completed - Clinical trials for Gastro Esophageal Reflux

Effect of Citalopram on Reflux Episodes in Healthy Volunteers

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

Citalopram is sometimes used in the treatment for gastro-esophageal reflux disease, however, there are no empirical data to support this. The investigators would like to know if citalopram has an effect on the lower esophageal sphincter pressure, transient lower esophageal sphincter relaxations and reflux episodes. The investigators will investigate this by performing high resolution impedance manometry in healthy volunteers before and after a solid meal. This will be compared to placebo, in a cross-over, randomized, double-blind condition.